Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Needham & Company LLC

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reaffirmed by stock analysts at Needham & Company LLC in a research note issued to investors on Friday, Benzinga reports. They presently have a $22.00 price objective on the stock. Needham & Company LLC’s target price points to a potential upside of 65.29% from the company’s current price.

A number of other research analysts have also weighed in on the stock. JPMorgan Chase & Co. raised their price target on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a research report on Tuesday, March 26th. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research note on Thursday, April 4th. Wedbush increased their price target on Stoke Therapeutics from $13.00 to $17.00 and gave the company an “outperform” rating in a research report on Tuesday, March 26th. TD Cowen upgraded Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 26th. Finally, Canaccord Genuity Group reduced their price objective on Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, May 7th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $20.57.

Stoke Therapeutics Stock Up 3.0 %

Shares of NASDAQ:STOK opened at $13.31 on Friday. Stoke Therapeutics has a twelve month low of $3.35 and a twelve month high of $17.58. The firm has a market capitalization of $693.72 million, a price-to-earnings ratio of -5.52 and a beta of 0.88. The stock’s 50 day moving average is $13.76 and its 200-day moving average is $9.30.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Monday, May 6th. The company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.03. The company had revenue of $4.22 million for the quarter, compared to the consensus estimate of $3.33 million. Equities research analysts anticipate that Stoke Therapeutics will post -2.3 earnings per share for the current fiscal year.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 3,600,000 shares of the business’s stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $11.60, for a total value of $41,760,000.00. Following the sale, the insider now directly owns 10,843,681 shares in the company, valued at $125,786,699.60. The sale was disclosed in a filing with the SEC, which is accessible through this link. 11.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Several large investors have recently added to or reduced their stakes in STOK. Lynx1 Capital Management LP lifted its holdings in Stoke Therapeutics by 25.0% during the first quarter. Lynx1 Capital Management LP now owns 3,696,820 shares of the company’s stock valued at $49,907,000 after purchasing an additional 739,902 shares during the last quarter. Artal Group S.A. bought a new stake in shares of Stoke Therapeutics in the first quarter valued at approximately $4,050,000. Redmile Group LLC lifted its stake in shares of Stoke Therapeutics by 93.2% during the 1st quarter. Redmile Group LLC now owns 5,073,049 shares of the company’s stock valued at $68,486,000 after buying an additional 2,447,543 shares in the last quarter. Baker BROS. Advisors LP boosted its holdings in Stoke Therapeutics by 65.9% in the 1st quarter. Baker BROS. Advisors LP now owns 3,368,443 shares of the company’s stock worth $45,474,000 after buying an additional 1,338,309 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Stoke Therapeutics by 5.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,431 shares of the company’s stock worth $425,000 after buying an additional 1,642 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.